Competition Law and Public–Private Innovation Partnerships

1. Introduction

Public–Private Innovation Partnerships (PPIPs) are collaborative arrangements in which a public authority, government agency, university, research institution, state-owned enterprise, or publicly funded body works with one or more private undertakings to develop, test, finance, commercialise, or procure innovative products and services.

Examples include:

• public–private AI research programmes;
• defence and dual-use technology projects;
• pharmaceutical and biotechnology R&D;
• smart-city and digital-infrastructure projects;
• renewable-energy and hydrogen technology partnerships;
• public health and vaccine development;
• transport and autonomous-mobility projects;
• university–industry research collaborations;
• public procurement of technologies that do not yet exist.

Competition law does not generally prohibit such cooperation. Innovation partnerships can reduce R&D costs, share risks, combine complementary expertise and accelerate technological development. However, competition concerns arise where the partnership becomes a mechanism for excluding competitors, sharing commercially sensitive information, controlling intellectual property, fixing prices, allocating markets, restricting access to essential technology, or creating an entrenched public-private monopoly.

The EU's horizontal-cooperation framework expressly recognises that R&D cooperation can involve undertakings, academic bodies and research institutes, while also warning that cooperation can reduce innovation or foreclose third parties.

2. Meaning of Public–Private Innovation Partnerships

A PPIP can take several forms:

A. Joint R&D venture

A government research body and private companies jointly develop a technology.

Example: A government laboratory and several technology companies jointly develop an advanced battery technology.

B. Innovation procurement

A public authority identifies a technological problem and contracts with private entities to develop a solution.

The EU's innovation partnership procurement model specifically permits a public buyer to establish a partnership for developing and subsequently purchasing an innovative solution. It remains a procurement procedure and therefore must respect competition, transparency and non-discrimination.

C. Publicly funded research consortium

Government provides grants while private companies contribute capital, technology or researchers.

D. Public-private joint venture

The government and private undertaking jointly control a separate company.

E. University–industry partnership

Universities or public research institutions cooperate with private companies to develop patents, software, pharmaceuticals or other technologies.

F. Technology-transfer partnership

The public sector funds research while a private company obtains commercialisation rights.

3. Competition-Law Framework

The competition-law analysis normally concerns five interconnected areas:

1. collaboration between competitors;
2. public procurement;
3. intellectual-property rights;
4. market power and exclusion;
5. state involvement and competitive neutrality.

The important question is not simply:

"Is this partnership innovative?"

Instead, the competition inquiry asks:

Does the partnership produce legitimate innovation efficiencies without unnecessarily eliminating competition in existing or future markets?

4. Pro-Competitive Effects

PPIPs can produce significant competition benefits.

4.1 Sharing R&D costs

Advanced technologies may require enormous investment.

A partnership can allow firms and public bodies to share:

• laboratories;
• computing infrastructure;
• testing facilities;
• researchers;
• patents;
• datasets;
• experimental facilities.

4.2 Risk sharing

Innovation frequently has uncertain outcomes.

A public-private partnership can distribute technological and financial risks between the parties.

4.3 Complementary capabilities

The public sector may possess:

• research infrastructure;
• datasets;
• regulatory expertise;
• testing facilities.

Private firms may possess:

• engineering capabilities;
• commercialisation expertise;
• manufacturing capacity;
• distribution networks.

Combining those assets can accelerate innovation.

4.4 Faster commercialisation

A successful PPIP can shorten the period between laboratory discovery and commercial deployment.

4.5 Creation of new markets

Competition law increasingly recognises innovation competition even where the relevant product market has not yet developed.

The European Commission's R&D guidance expressly considers situations where cooperation concerns technologies capable of creating an entirely new market.

5. Principal Competition Concerns

5.1 Collusion disguised as innovation cooperation

Two competitors may create a genuine R&D project but simultaneously use the partnership to coordinate:

• prices;
• output;
• customers;
• production;
• investment;
• future product launches.

The legitimate R&D purpose does not immunise unrelated restraints.

Example

Two competing pharmaceutical companies jointly develop a drug but agree that neither will independently develop competing treatments.

The R&D cooperation may therefore suppress innovation competition.

6. Information Exchange

Innovation partnerships frequently require extensive information sharing.

Information can include:

• R&D expenditure;
• future product plans;
• technological roadmaps;
• production costs;
• customer information;
• pricing strategies;
• patent strategies;
• commercial forecasts.

The danger is particularly high where competitors participate in the same partnership.

A public authority must therefore establish appropriate:

• confidentiality protocols;
• information-access rules;
• data segmentation;
• clean teams;
• cybersecurity arrangements;
• need-to-know systems.

7. Intellectual Property and Competition

IP rights are often central to PPIPs.

The partnership agreement should determine:

• who owns newly created patents;
• who owns background IP;
• who receives licences;
• whether licences are exclusive;
• geographical scope;
• field-of-use restrictions;
• royalty arrangements;
• publication rights;
• rights after termination.

Competition concern

Suppose a public research institution develops a technology using substantial taxpayer funding and grants one private undertaking an exclusive perpetual licence.

If the technology is indispensable for competing in a downstream market, the exclusive arrangement may potentially foreclose competitors.

8. Access to Publicly Funded Technology

One of the most important competition-policy questions is:

Should technology developed with public resources remain accessible to competitors?

Possible approaches include:

Open licensing

Technology is licensed to multiple market participants.

FRAND licensing

Technology is made available on fair, reasonable and non-discriminatory terms.

Non-exclusive licensing

Several firms can commercialise the technology.

Exclusive licensing

One undertaking receives exclusive commercial rights.

Exclusive licensing may be justified where it is necessary to recover substantial investment, but excessive exclusivity can create competition problems.

9. Public Procurement Dimension

A PPIP frequently culminates in public procurement.

This creates a second competition layer.

The public authority must avoid:

• designing specifications for a predetermined company;
• excluding alternative technologies unnecessarily;
• sharing one bidder's confidential information with another;
• favouring an incumbent partner;
• extending an innovation contract indefinitely without competitive review.

The EU specifically recognises that an innovation partnership is still a public procurement procedure, notwithstanding its collaborative structure.

10. Market Foreclosure

A partnership can become problematic when participating firms control an important technological input.

Potential foreclosure mechanisms include:

• refusing licences;
• exclusive access to public datasets;
• exclusive access to testing facilities;
• interoperability restrictions;
• technical standards controlled by incumbents;
• exclusion from public infrastructure;
• discriminatory access terms.

This is particularly significant in:

• AI;
• cloud computing;
• telecommunications;
• pharmaceuticals;
• energy;
• transport;
• defence technology;
• digital infrastructure.

11. Essential Facilities and Innovation Partnerships

Where the partnership creates infrastructure that competitors cannot reasonably reproduce, essential-facility-type concerns may arise.

Examples:

• publicly funded supercomputing infrastructure;
• government-owned spectrum infrastructure;
• national research databases;
• specialised testing laboratories;
• national charging infrastructure;
• public genomic databases.

If a private partner obtains preferential access, the competition authority may examine whether competitors are unfairly excluded.

12. Competition Neutrality

Public participation can create advantages unavailable to private competitors.

Potential advantages include:

• government guarantees;
• subsidised land;
• preferential financing;
• exclusive regulatory permissions;
• government-owned infrastructure;
• privileged access to public data;
• tax benefits;
• preferential procurement.

The existence of public funding does not automatically make an arrangement unlawful. The relevant issue is whether government intervention creates unjustified competitive advantages or supports exclusionary conduct.

13. Relevant Case Laws

Because there are relatively few reported decisions specifically titled "public-private innovation partnership", the most useful authorities come from EU and US competition jurisprudence concerning R&D cooperation, technology access, IP, joint ventures, public procurement, standardisation and innovation markets.

Case 1: Bayer AG and Sandoz / Adalat

Principle: Agreements affecting independent commercial decision-making may violate competition law even where the parties have legitimate commercial relationships.

Relevance

Public-private innovation partnerships must separate legitimate collaborative R&D from restrictions concerning:

• commercial independence;
• market allocation;
• pricing;
• supply;
• distribution.

The fact that parties cooperate technologically does not allow them to coordinate their independent market behaviour.

Lesson

Innovation cooperation cannot be used as a vehicle for broader commercial coordination.

14. Case 2: European Commission – CECED

CECED concerned cooperation relating to energy-efficient household appliances.

Principle

The Commission examined an industry agreement involving environmental and energy-efficiency objectives and recognised that cooperation could generate benefits while also affecting competition.

Relevance to PPIPs

It demonstrates that agreements pursuing legitimate public-policy objectives can still require competition analysis.

A government objective such as:

• decarbonisation;
• energy efficiency;
• public health;
• technological development;

does not automatically remove competition-law scrutiny.

Lesson

Public-interest objectives and competition analysis must be assessed together.

15. Case 3: IMS Health GmbH & Co. OHG v NDC Health

Court of Justice of the European Union, Case C-418/01

Facts

IMS Health controlled a copyright-related structure used for pharmaceutical sales-data services.

Principle

The Court developed strict conditions concerning when refusal to license an intellectual-property right by a dominant undertaking can constitute an abuse.

Relevance

Suppose a public-private research partnership creates a dataset, technology or technical architecture that becomes indispensable for competitors.

If the private partner obtains control over that indispensable technology, refusal to provide access may raise Article 102-type concerns.

Lesson

Innovation-related IP rights can become competition-law issues where control over the technology creates significant market power.

16. Case 4: Microsoft Corp. v Commission

General Court, Case T-201/04

Principle

A dominant technology undertaking can violate competition law where it uses control over an important technological interface or information resource to restrict competition in neighbouring markets.

Relevance to PPIPs

A public-private technology project may produce:

• APIs;
• interoperability protocols;
• technical interfaces;
• databases;
• software infrastructure.

If the private partner controls such an interface and uses it to disadvantage downstream competitors, competition concerns can arise.

Lesson

Technological interoperability can be a competition-law issue when access to technology affects downstream competition.

17. Case 5: Magill TV Guide

Joined Cases C-241/91 P and C-242/91 P

Principle

The Court recognised that, in exceptional circumstances, exercise of an intellectual-property right can amount to abuse of dominance.

Relevance

A PPIP may generate publicly supported IP that becomes essential to development of subsequent products.

If the partnership gives one participant excessive control over indispensable IP, the structure should be assessed for possible foreclosure.

Lesson

IP ownership is not an absolute shield against competition law.

18. Case 6: AstraZeneca v Commission

Case C-457/10 P

Principle

The case concerned misuse of regulatory and patent-related mechanisms by a dominant pharmaceutical undertaking.

Relevance to PPIPs

Public-private pharmaceutical partnerships may involve:

• patents;
• regulatory approvals;
• public research;
• exclusivity;
• data protection;
• licensing.

Competition law can examine whether regulatory or IP mechanisms are used strategically to exclude rivals rather than simply to protect legitimate innovation.

Lesson

Regulatory and intellectual-property rights cannot necessarily be used to create artificial barriers to competition.

19. Case 7: American Needle, Inc. v NFL

U.S. Supreme Court, 2010

Principle

The Supreme Court examined whether separately owned entities could be treated as a single entity for antitrust purposes.

The Court emphasised that entities remain capable of conspiring when they pursue separate economic interests.

Relevance

This is highly relevant to public-private innovation ventures.

A partnership may contain:

• government bodies;
• universities;
• private companies;
• competing manufacturers;
• technology suppliers.

Calling them "partners" does not automatically remove antitrust scrutiny.

Lesson

The legal form of collaboration is less important than the economic independence of the participants.

20. Case 8: Broadcast Music, Inc. v CBS

U.S. Supreme Court, 1979

Principle

Not every agreement among competitors is automatically treated as a per se unlawful restraint.

Some collaboration may create a new product or service that individual firms could not efficiently provide independently.

Relevance

This provides an important counterbalance to excessive competition-law intervention in PPIPs.

Where collaboration creates genuine efficiencies—such as:

• shared technology;
• common licensing infrastructure;
• joint research;
• reduced transaction costs;

the agreement may require a rule-of-reason/effects-based assessment rather than automatic condemnation.

Lesson

Competition law should distinguish genuinely productive collaboration from cartel-like coordination.

21. Case 9: FTC v. Actavis

U.S. Supreme Court, 2013

Principle

The Court examined the competitive consequences of agreements involving pharmaceutical patent rights and payments between firms.

Relevance

Public-private pharmaceutical partnerships may involve:

• patent licences;
• exclusivity;
• technology transfer;
• payments;
• delayed market entry.

An arrangement ostensibly connected with innovation or patent settlement may nevertheless have substantial effects on future competition.

Lesson

The economic substance of the arrangement matters more than its contractual label.

22. Case 10: Meca-Medina v Commission

Case C-519/04 P

Principle

Even rules associated with legitimate non-economic objectives can fall within competition law where they have economic effects.

Relevance

A public-private innovation programme justified by:

• public health;
• safety;
• environmental objectives;
• technological development;

may still require competition assessment if it affects economic competition.

Lesson

Public-interest objectives do not automatically place economically significant arrangements outside competition law.

23. Indian Competition-Law Relevance

For India, the principal statutory framework is the Competition Act, 2002.

Important provisions include:

Section 3

Prohibits agreements causing or likely to cause an appreciable adverse effect on competition (AAEC).

This is particularly relevant to:

• R&D collaborations;
• technology-sharing arrangements;
• joint ventures;
• consortium agreements;
• licensing arrangements.

Section 4

Deals with abuse of dominant position.

Potential issues include:

• discriminatory access;
• denial of market access;
• unfair conditions;
• leveraging dominance;
• tying;
• exclusive arrangements.

Sections 5 and 6

Concern combinations and therefore become relevant where an innovation partnership involves acquisition of control, merger or joint venture.

24. CCI Case: Shamsher Kataria v Honda Siel Cars India Ltd. & Ors.

Case No. 03/2011

This important Indian competition case concerned the automobile aftermarket and access to technical information, spare parts and diagnostic tools.

Relevance to innovation partnerships

Public-private technology partnerships may similarly create control over:

• technical information;
• diagnostic systems;
• proprietary software;
• technical databases;
• replacement technology.

If access is restricted in a way that excludes independent competitors, Section 4 concerns may arise.

Principle

Control over technologically important inputs can have competitive consequences in downstream markets.

25. CCI Case: Google Android

The CCI's Android proceedings examined Google's contractual arrangements involving the Android ecosystem, including restrictions affecting access and distribution.

Relevance

Innovation partnerships increasingly operate through ecosystems rather than standalone products.

A PPIP involving:

• cloud infrastructure;
• AI models;
• operating systems;
• APIs;
• public digital infrastructure;

may create similar ecosystem effects.

Lesson

A partnership should not use control over one technological layer to unnecessarily foreclose competition at another layer.

26. CCI Case: Google Play Billing

The CCI's proceedings concerning Google's Play Store ecosystem demonstrate the significance of:

• platform access;
• payment systems;
• mandatory technical arrangements;
• app distribution;
• ecosystem dependency.

Relevance

A public-private digital innovation platform may similarly become a gatekeeper.

If participating private firms obtain preferential access to public digital infrastructure, competition authorities may examine whether competitors are being disadvantaged.

27. Competition Issues in Public–Private Innovation Partnerships

28. Innovation Competition

A particularly important modern concept is competition for innovation.

Traditional competition analysis asks:

Who currently sells the product?

Innovation competition asks:

Who is developing the next generation of the product?

This is especially relevant to:

• AI;
• quantum computing;
• biotechnology;
• hydrogen;
• semiconductors;
• autonomous vehicles;
• batteries;
• carbon capture;
• advanced telecommunications.

The EU's current horizontal guidelines expressly recognise that R&D cooperation can affect competition in innovation, including innovation that may eventually create entirely new markets.

29. Future-Market Foreclosure

Suppose three companies are developing competing hydrogen-storage technologies.

A government establishes a public-private innovation partnership with two of them.

The partnership:

1. gives the two companies exclusive access to government research;
2. provides them with the only large-scale testing facility;
3. gives them exclusive access to public datasets;
4. prevents participating researchers from working with outsiders.

Even if the partnership accelerates technological development, it could potentially eliminate the third company's innovation pathway.

This illustrates why future competition matters.

30. Bid-Rigging Through Innovation Consortia

Public procurement creates a special danger.

Suppose four technology companies normally compete for a government contract.

They form a consortium and submit one joint bid.

The arrangement could be legitimate if:

• no individual member can perform the contract;
• complementary capabilities are genuinely required;
• the collaboration produces efficiencies.

But it may be problematic if:

• each participant could independently bid;
• the consortium eliminates meaningful competition;
• members agree not to submit separate bids;
• members exchange pricing information.

Competition authorities therefore distinguish legitimate bidding consortia from arrangements functioning as bid-rigging mechanisms.

31. Public Procurement and Innovation Partnerships

The EU model illustrates an important structural principle.

An innovation partnership can involve several stages:

Stage 1 — Identification

Government identifies an unmet technological need.

Stage 2 — Selection

Potential innovators compete for partnership.

Stage 3 — R&D

The selected partners develop prototypes.

Stage 4 — Evaluation

Performance is assessed against predetermined criteria.

Stage 5 — Commercialisation

The successful solution can be purchased by the public authority.

The competition safeguards must operate throughout the process.

The EU framework specifically emphasises the need for market pull without foreclosing the market.

32. Public Funding and State-Aid Considerations

Where a government provides financial support to private companies, a second legal question may arise:

Does the funding provide a selective economic advantage?

In jurisdictions such as the EU, state-aid rules may therefore operate alongside competition rules.

Important factors include:

• whether funding is provided on market terms;
• whether private investors share equivalent risk;
• whether the beneficiary receives selective advantages;
• whether the support affects competition;
• whether the support is proportionate to the innovation objective.

33. Designing a Competition-Compliant PPIP

A well-designed partnership should contain:

1. Clearly defined objectives

Specify precisely what innovation the partnership seeks to develop.

2. Competitive selection

Use objective and transparent selection criteria.

3. Limited exclusivity

Exclusive rights should be used only where genuinely necessary.

4. IP governance

Clearly distinguish:

• background IP;
• foreground IP;
• jointly developed IP.

5. Access provisions

Specify whether third parties can obtain access to:

• data;
• infrastructure;
• patents;
• APIs;
• standards.

6. Information barriers

Limit access to competitively sensitive information.

7. Independent decision-making

Participants should remain free to compete outside the partnership.

8. Procurement safeguards

Avoid specifications tailored to one incumbent.

9. Periodic review

Long-term partnerships should be reviewed as markets evolve.

10. Exit mechanisms

Participants should be able to leave without creating unnecessary competitive restrictions.

34. Competition Compliance Checklist

Before establishing a PPIP, the parties should ask:

A. Market

• Who are the current competitors?
• Who are potential future competitors?
• Is there an emerging innovation market?

B. Participants

• Are participants actual competitors?
• Are they potential competitors?
• Do they operate at different levels of the supply chain?

C. Information

• What information must be shared?
• Is it competitively sensitive?
• Can clean teams be used?

D. IP

• Who owns the resulting IP?
• Is licensing exclusive?
• Can competitors obtain licences?

E. Procurement

• Was the selection process transparent?
• Could alternative suppliers participate?
• Does the contract favour the incumbent unnecessarily?

F. Market access

• Will competitors obtain access to essential infrastructure?
• Are technical interfaces interoperable?

G. Duration

• Is exclusivity limited to the period necessary to incentivise investment?

35. Balancing Innovation and Competition

The central competition-law problem can be expressed as follows:

Public objective

↓

Need for technological innovation

↓

Public-private collaboration

↓

Sharing of resources + knowledge + risk

↓

Potential innovation efficiencies

BUT

↓

Information exchange / exclusivity / IP control / market foreclosure

↓

Potential restriction of competition

Therefore, competition law should not treat every PPIP as suspicious. Nor should public participation provide an automatic exemption from competition rules.

The appropriate approach is generally effects-based and proportionate: identify the legitimate innovation objective, examine the competitive restraints, determine whether those restraints are necessary, and assess whether less restrictive mechanisms could achieve the same innovation benefits. The EU's R&D framework expressly recognises both sides of this equation.

36. Conclusion

Public–Private Innovation Partnerships occupy an important intersection between competition law, public procurement, intellectual-property law and innovation policy.

They can generate substantial benefits by:

• pooling capital;
• sharing technological risks;
• combining public and private expertise;
• accelerating R&D;
• creating new products;
• improving public services;
• commercialising publicly funded research.

However, they can also create competition problems where they:

• eliminate independent innovation;
• facilitate coordination between competitors;
• restrict access to publicly funded technology;
• create exclusive technological ecosystems;
• discriminate against rival suppliers;
• foreclose future competitors;
• manipulate public procurement;
• or transform public infrastructure into a privately controlled bottleneck.

The key legal principle is therefore:

A public-private innovation partnership should promote innovation without unnecessarily eliminating the competitive process that drives innovation.

The most relevant authorities—from CECED, Magill, IMS Health, Microsoft, AstraZeneca, American Needle, Broadcast Music and Actavis, together with Indian CCI jurisprudence such as Shamsher Kataria and the Google cases—demonstrate the recurring competition-law themes of collaboration, innovation, IP access, interoperability, information exchange, market power and foreclosure.